within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AX07_Ibrexafungerp;

model Ibrexafungerp
  extends Pharmacolibrary.Drugs.ATC.J.J02AX07
  // parameters inherited from base class, duplicate, uncomment and change if necesarry
  /*
  
    weight         = 70,
    F              = 0.35,
    Cl             = 6.944444444444445e-06,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.6,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0014166666666666668,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.43,
    k12             = 2.4999999999999998e-05,
    k21             = 2.4999999999999998e-05
      
  */
  ;

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ibrexafungerp</td></tr><tr><td>ATC code:</td><td>J02AX07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>600</td><td>L</td></tr>
    <tr><td>clearance:</td><td>25</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ibrexafungerp is a novel triterpenoid antifungal agent, approved for the treatment of vulvovaginal candidiasis (VVC) and is under investigation for other serious fungal infections. It has activity against a wide spectrum of Candida species, including strains resistant to azoles and echinocandins. Ibrexafungerp is orally administered and is the first-in-class oral glucan synthase inhibitor, representing a new option for antifungal therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects following oral administration.</p><h4>References</h4><ol><li><p>Spec, A, et al., &amp; Pappas, PG (2019). MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>The Journal of antimicrobial chemotherapy</i> 74(10) 3056â€“3062. DOI:<a href=\"https://doi.org/10.1093/jac/dkz277\">10.1093/jac/dkz277</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31304536/\">https://pubmed.ncbi.nlm.nih.gov/31304536</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ibrexafungerp;
